EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of patient-derived HPV16 E6 and E7 variant alleles

Miranda Grace, Harshita Beeravolu, Ahmad Alhamshari, Josipa Skelin, Si-Young Kiessling, Andrew Bohm, Elizabeth A White iD, Karl Munger iD

Journal of Virology · 21.04.2026 · 100 (4)

DOI: 10.1128/jvi.00236-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 21.04.2026. Verfasst von Miranda Grace und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Oncogene Proteins, Viral, Repressor Proteins, Papillomavirus E7 Proteins, Human papillomavirus 16. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human papillomavirus type 16 (HPV16) is the most prevalent carcinogenic HPV type. Many HPV16 sequence variants have been described, some of which cause protein-coding mutations. However, most experiments have characterized the viral proteins encoded by the HPV16 prototype clone, and some researchers have proposed that variants identified in high-grade lesions and cancers may have higher oncogenic potential than the prototype. To determine whether oncoproteins encoded by such variants have greater oncogenic potential than the prototype version, we performed a comparative biochemical analysis of selected naturally occurring HPV16 E6 and E7 variant alleles identified in cervical lesions and/or control samples. We examined interactions of prototype and HPV16 E7 variant alleles with the retinoblastoma tumor suppressor pRB, the ubiquitin ligase UBR4 (p600), and the tumor suppressor PTPN14. We also compared HPV16 E6 prototype and variant protein interactions with the p53 tumor suppressor, the UBE3A (E6AP) ubiquitin ligase, and the PDZ-domain protein SCRIB. Several E6 or E7 variant proteins exhibited reduced binding to these cellular targets, suggestive of partial or complete loss of function. Our findings reveal that protein–protein interactions that enable the oncogenic activities of HPV16 E6 and E7 can be missing from naturally occurring HPV16 variants and that bona fide loss-of-function variants can be detected in high-grade cervical lesions or cancers. We conclude that clinical association alone is insufficient to predict the pathogenic potential of HPV16 E6 or E7 variant proteins. IMPORTANCE Human papillomavirus type 16 (HPV16) is the leading cause of HPV-associated cancers, and most functional studies have been performed with the prototype viral clone. Numerous naturally occurring HPV16 variants have been detected in cervical lesions and cancers, raising the possibility that some variants may possess enhanced transforming activity. E6 and E7 are the major oncoproteins encoded by HPV16. By comparing key molecular interactions of prototype and naturally occurring E6 and E7 variant proteins, we found that several variant proteins display reduced engagement with tumor suppressors and ubiquitin ligases that are important for oncogenic activities. Notably, some variants found in high-grade lesions and cancers show partial or complete loss of engaging these critical host proteins. These findings indicate that the presence of an HPV16 variant in a cancer does not necessarily imply increased oncogenic potency. Functional characterization is therefore essential to interpret the biological and clinical significance of HPV16 genetic diversity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncogene Proteins, ViralRepressor ProteinsPapillomavirus E7 ProteinsHuman papillomavirus 16Papillomavirus InfectionsHumansFemaleUbiquitin-Protein LigasesAllelesProtein BindingUterine Cervical NeoplasmsCalmodulin-Binding Proteins

Stichwörter der Autor:innen

E6 and E7 variant proteinsHPV16cervical carcinogenesisoncogenic mechanismsprotein–protein interactions

Substanzen

Oncogene Proteins, ViralE6 protein, Human papillomavirus type 16Repressor ProteinsPapillomavirus E7 Proteinsoncogene protein E7, Human papillomavirus type 16Ubiquitin-Protein LigasesUBE3A protein, humanUBR4 protein, humanCalmodulin-Binding Proteins

Autor:innen und Institutionen

  • Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA.

ORCID-Profile: Elizabeth A White, Karl Munger

Zitieren

APA

Grace, M., Beeravolu, H., Alhamshari, A., Skelin, J., Kiessling, S. Y., Bohm, A., White, E. A., & Munger, K. (2026). Characterization of patient-derived HPV16 E6 and E7 variant alleles. Journal of Virology, 100(4). https://doi.org/10.1128/jvi.00236-26

Vancouver

Grace M, Beeravolu H, Alhamshari A, Skelin J, Kiessling SY, Bohm A, et al. Characterization of patient-derived HPV16 E6 and E7 variant alleles. Journal of Virology. 2026;100(4). doi:10.1128/jvi.00236-26

BibTeX
@article{Grace2026,
  author = {Grace, Miranda and Beeravolu, Harshita and Alhamshari, Ahmad and Skelin, Josipa and Kiessling, Si-Young and Bohm, Andrew and White, Elizabeth A and Munger, Karl},
  title = {Characterization of patient-derived HPV16 E6 and E7 variant alleles},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {4},
  doi = {10.1128/jvi.00236-26}
}
Kostenlos starten →